Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/31372
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kowark, Ana | en_US |
dc.contributor.author | Berger, Moritz | en_US |
dc.contributor.author | Rossaint, Rolf | en_US |
dc.contributor.author | Schmid, Matthias | en_US |
dc.contributor.author | Coburn, Mark | en_US |
dc.contributor.author | POSE Study Group | en_US |
dc.contributor.author | Naumovski, Filip | en_US |
dc.date.accessioned | 2024-09-25T10:16:06Z | - |
dc.date.available | 2024-09-25T10:16:06Z | - |
dc.date.issued | 2021-11-25 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12188/31372 | - |
dc.description.abstract | Recent guidelines suggest that benzodiazepine premedication should be avoided in elderly patients, though with limited supporting evidence. We conducted a secondary analysis of the POSE data to explore the association of premedication in patients aged 80 years or older with 30-day mortality. We used propensity score methods to perform a confounder-adjusted time-to-event analysis of the association between benzodiazepine premedication and 30-day mortality of the POSE study. POSE was conducted as a European multicentre prospective cohort study. PATIENTS Adults aged 80 years or older scheduled for surgical or nonsurgical intervention under anaesthesia. RESULTS A total of 9497 patients were analysed. One thousand five hundred and twenty-one patients received benzodiazepine premedication, 7936 patients received no benzodiazepine premedication, 30 received clonidine and 10 had missing premedication data. Inverse propensity-score-weighted log-rank analysis did not provide unambiguous evidence for an association between benzodiazepine premedication and 30-day mortality; median [range] <jats:italic toggle="yes">P</jats:italic> = 0.048 [0.044 to 0.078], estimated 30-day mortality rates 3.21% and 4.45% in benzodiazepine-premedicated and nonbenzodiazepine-premedicated patients, respectively. Inverse propensity-score-weighted Cox regression resulted in a hazard ratio of 0.71 (95% CI 0.49 to 1.04), pointing at a possible reduction of 30-day mortality in the benzodiazepine premedication group. Sensitivity analyses, which constituted subgroup, matched-pairs, and sub classification analyses, resulted in similar findings. CONCLUSION This secondary analysis of the POSE data did not find evidence for an unambiguous association between benzodiazepine premedication and 30-day mortality. Point estimates indicated a reduction of 30-day mortality in benzodiazepine-premedicated patients. The results presented here might be affected by unmeasured confounding factors, which could be addressed in a randomised trial. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Ovid Technologies (Wolters Kluwer Health) | en_US |
dc.relation.ispartof | European Journal of Anaesthesiology | en_US |
dc.title | Association between benzodiazepine premedication and 30-day mortality rate | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1097/eja.0000000000001638 | - |
dc.identifier.url | https://journals.lww.com/10.1097/EJA.0000000000001638 | - |
dc.identifier.volume | 39 | - |
dc.identifier.issue | 3 | - |
dc.identifier.fpage | 210 | - |
dc.identifier.lpage | 218 | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Association between benzodiazepine premedication and 30 day mortality rate.pdf | 437.06 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.